Holen Sie sich die Stockscreener-App
7.83
0.38%
0.03
Handel nachbörslich:
7.83
Schlusskurs vom Vortag:
$7.80
Offen:
$7.83
24-Stunden-Volumen:
1.28M
Relative Volume:
0.43
Marktkapitalisierung:
$1.64B
Einnahmen:
$331.41M
Nettoeinkommen (Verlust:
$-226.54M
KGV:
-6.6356
EPS:
-1.18
Netto-Cashflow:
$-97.31M
1W Leistung:
+1.82%
1M Leistung:
-7.56%
6M Leistung:
+2.76%
1J Leistung:
+52.04%
1-Tages-Spanne:
$7.75
$7.8847
1-Wochen-Bereich:
$7.60
$8.12
52-Wochen-Spanne:
$4.03
$9.50
Biocryst Pharmaceuticals Inc Stock (BCRX) Company Profile
Firmenname
Biocryst Pharmaceuticals Inc
Sektor
Telefon
919-859-1302
Adresse
4505 EMPEROR BOULEVARD, DURHAM, NC
Vergleichen Sie BCRX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BCRX
Biocryst Pharmaceuticals Inc
|
7.83 | 1.64B | 331.41M | -226.54M | -97.31M | -1.18 |
|
ZTS
Zoetis Inc
|
165.02 | 73.07B | 9.26B | 2.49B | 2.30B | 5.47 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.14 | 47.43B | 30.25B | 1.37B | 5.08B | 0.4257 |
|
HLN
Haleon Plc Adr
|
10.12 | 45.72B | 14.35B | 1.85B | 0 | 0.4023 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
15.49 | 17.75B | 16.54B | -1.64B | 749.00M | -1.45 |
|
ITCI
Intra Cellular Therapies Inc
|
131.75 | 14.03B | 612.78M | -86.37M | -62.91M | -0.87 |
Biocryst Pharmaceuticals Inc Stock (BCRX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-02-25 | Eingeleitet | Wedbush | Outperform |
| 2023-11-20 | Fortgesetzt | JP Morgan | Overweight |
| 2023-09-18 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2023-08-04 | Hochstufung | Jefferies | Hold → Buy |
| 2023-07-13 | Hochstufung | BofA Securities | Neutral → Buy |
| 2023-02-22 | Hochstufung | Needham | Hold → Buy |
| 2022-11-02 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2022-08-05 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2022-08-05 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2022-04-18 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2022-04-11 | Herabstufung | BofA Securities | Buy → Neutral |
| 2021-12-10 | Eingeleitet | Oppenheimer | Outperform |
| 2021-08-06 | Herabstufung | Jefferies | Buy → Hold |
| 2021-08-03 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2021-03-01 | Eingeleitet | Cowen | Outperform |
| 2020-09-29 | Fortgesetzt | JP Morgan | Overweight |
| 2020-06-17 | Eingeleitet | BTIG Research | Neutral |
| 2020-05-05 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2019-11-15 | Hochstufung | BofA/Merrill | Neutral → Buy |
| 2019-05-24 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2018-11-16 | Fortgesetzt | Piper Jaffray | Overweight |
| 2018-08-08 | Fortgesetzt | JP Morgan | Overweight |
| 2018-07-17 | Hochstufung | BofA/Merrill | Underperform → Neutral |
| 2018-06-22 | Eingeleitet | Seaport Global Securities | Neutral |
| 2018-01-02 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2017-12-20 | Eingeleitet | Barclays | Equal Weight |
| 2017-09-15 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2017-09-06 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2017-09-06 | Hochstufung | Jefferies | Hold → Buy |
| 2017-02-16 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2016-08-12 | Hochstufung | Piper Jaffray | Neutral → Overweight |
| 2016-08-04 | Herabstufung | JMP Securities | Mkt Outperform → Mkt Perform |
| 2016-02-09 | Bestätigt | FBR Capital | Outperform |
| 2016-02-09 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2016-02-09 | Herabstufung | Needham | Buy → Hold |
Alle ansehen
Biocryst Pharmaceuticals Inc Aktie (BCRX) Neueste Nachrichten
BioCryst's Booming HAE Drug Sales Set The Stage For A Strong 2025Will The Stock Follow? - RTTNews
North Carolina biotech sues to block copies of $400M drug - The Business Journals
Institutional investors control 75% of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) and were rewarded last week after stock increased 4.9% - Yahoo Finance
Groundbreaking Step in Battling Angioedema at UC San Diego - University of California San Diego
The 4.9% return this week takes BioCryst Pharmaceuticals' (NASDAQ:BCRX) shareholders five-year gains to 295% - Simply Wall St
(BCRX) Technical Data - Stock Traders Daily
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Receives Average Recommendation of “Moderate Buy” from Brokerages - Defense World
25,583 Shares in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Bought by Proficio Capital Partners LLC - Defense World
BioCryst’s SWOT analysis: orladeyo success fuels growth amid competition By Investing.com - Investing.com South Africa
BioCryst’s SWOT analysis: orladeyo success fuels growth amid competition - Investing.com
BioCryst at Barclays Conference: Strategic Growth and Pipeline Focus By Investing.com - Investing.com Canada
BioCryst sues to protect ORLADEYO patents By Investing.com - Investing.com Canada
BioCryst Sues Hetero to Block Copies of Drug Worth $386 Million - Bloomberg Law
BioCryst takes legal action to defend rare genetic drug patent; shares fall - TradingView
BioCryst sues to protect ORLADEYO patents - Investing.com India
Biocryst PharmaceuticalsOn March 10, Files Patent Infringement Lawsuit Against Annora And Other Co's - Marketscreener.com
Insider Buying: Chief R&D Officer Helen Thackray Acquires 30,000 Shares of BioCryst Pharmaceuticals Inc (BCRX) - GuruFocus.com
Principal Financial Group Inc. Sells 393,607 Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) - Defense World
Orladeyo safely prevents swelling attacks in young children with HAE - Angioedema News Today
BioCryst at TD Cowen Conference: Strategic Growth Insights - Investing.com
BioCryst at TD Cowen Conference: Strategic Growth Insights By Investing.com - Investing.com UK
BioCryst Pharmaceuticals Inc (BCRX) Announces Grant of Restricted Stock Units to New Employees - GuruFocus.com
BioCryst reports inducement grants under Nasdaq listing rule - TipRanks
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
BioCryst's Latest Employee Stock Awards: Key Details on 65,900 RSU Grants - StockTitan
BioCryst CFO resigns, search for successor begins By Investing.com - Investing.com Australia
CFO Anthony Doyle resigns at Biocryst - BioCentury
BioCryst CFO resigns, search for successor begins - Investing.com India
BioCryst CFO Anthony Doyle Resigns Effective April 2025 - TipRanks
Where are the Opportunities in (BCRX) - Stock Traders Daily
Rhumbline Advisers Has $2.33 Million Stock Holdings in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) - Defense World
BioCryst stock holds $18 target, JMP bullish on trial results By Investing.com - Investing.com Canada
Is BioCryst Pharmaceuticals, Inc. (BCRX) the Best Small-Cap Stock to Buy Now? - MSN
Here's Why BioCryst (BCRX) Could be Great Choice for a Bottom Fisher - MSN
10 Best Small-Cap Stocks to Buy Now - Insider Monkey
BioCryst Pharmaceuticals' (BCRX) "Outperform" Rating Reaffirmed at Royal Bank of Canada - MarketBeat
Wedbush Initiates Coverage on BioCryst Pharmaceuticals (NASDAQ:BCRX) - MarketBeat
HC Wainwright Reiterates Buy Rating for BioCryst Pharmaceuticals (NASDAQ:BCRX) - MarketBeat
Analysts Set Expectations for BCRX Q1 Earnings - Defense World
BioCryst Pharmaceuticals (NASDAQ:BCRX) Issues Earnings Results - MarketBeat
BioCryst stock soars to 52-week high, touches $9.02 - MSN
BioCryst (BCRX) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates - Yahoo Finance
BioCryst Pharmaceuticals (NASDAQ:BCRX) Shares Gap Down Following Weak Earnings - MarketBeat
Wall Street Analysts Predict an 84.18% Upside in BioCryst (BCRX): Here's What You Should Know - MSN
Finanzdaten der Biocryst Pharmaceuticals Inc-Aktie (BCRX)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.46%
0.47%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):